Pfeiffer syndrome (PS, OMIM #101600) is an inherited craniofacial disorder that is associated with primary craniosynostosis, midface hypoplasia, broad thumbs and great toes, and soft tissue syndactyly of hands (usually second and third digits) and feet of varying severity.[1] Most of the affected patients have associated conductive hearing loss.
Rudolf Pfeiffer first described a syndrome of acrocephalosyndactyly associated with hypertelorism, antimongoloid slant, broad thumbs, great toes, and normal intelligence in 1964. He reported 8 cases through 3 generations of a family, with two instances of male-to-male transmission, suggesting an autosomal dominant mode of inheritance.[2]
It is also known as type V acrocephalosyndactyly, craniofacial-skeletal-dermatologic dysplasia, or Noack syndrome.
Acrocephalosyndactyly syndromes involving premature closing of the cranial sutures are:
PS has a characteristic autosomal dominant inheritance with complete penetrance with variable expressivity in terms of syndactyly.[3]
PS type I is associated with mutations in FGFR1 and FGFR2. PS type II and type III are associated with mutations in FGFR2. PS is most commonly caused by mutations in the FGFR2 gene (on chromosome 10q26.13). Mutations in the FGFR1 gene (on chromosome 8p11.23) cause a small percentage of cases of type I PS only and usually are not associated with other types of PS. The FGFR1 and FGFR2 genes are responsible for the production of fibroblast growth factor receptors 1 and 2, respectively. These receptors are mainly involved in the transformation of pluripotent stem cells to osteoblasts during embryonic development. Mutations in these genes can lead to prolonged protein signaling, which leads to premature fusion of cranial bones and maldevelopment of extremity bones. Four major FGFR2 mutations p.W290C, p.Y340C, p.C342R, and p.S351C are responsible for severe forms of PS; whereas, FGFR1 p.P252R mutation usually gives rise to a relatively mild phenotype.[4] A specific mutation found in PS is Pro252Arg in exon 5 of FGFR1 locus.[5]
One major risk factor for the development of PS is advanced paternal age. The risk of an offspring getting affected with PS from an affected parent is 50% for each pregnancy. Both males and females have equal risks of affliction.
A cloverleaf skull usually results from premature closure of the coronal and lambdoid sutures. Bi-coronal synostosis can lead to skull base hypoplasia leading to reduced intracranial volume. This can lead to a rise in intracranial pressure (ICP), which can present as headache or visual disturbance. Another cause of hydrocephalus is the aqueductal stenosis, which is seen rarely in these patients. Characteristic facial features of PS result from the premature fusion of the skull bones. Abnormal growth of these bones leads to proptosis, wide-set eyes, a high forehead, an underdeveloped maxilla, and a beaked nose. Patients with PS may manifest upper airway obstruction related to midface hypoplasia and secondary nasal obstruction.
Maxillary hypoplasia leads to a reduced intra-orbital volume, which ultimately results in the development of proptosis, xerophthalmia, and exposure keratitis. Visual disturbances can be due to extraocular muscle imbalance secondary to proptosis or due to raised intracranial pressure. Hearing loss can be due to recurrent ear infections, hypoplasia of middle ear, or auditory canal atresia. Maxillary hypoplasia also results in reduced space of nasopharynx, oropharynx, and larynx leading to snoring, nasal regurgitation, aspiration of food, and obstructive sleep apnea.
PS type I is characterized by brachycephaly (due to bi-coronal synostosis), maxillary hypoplasia, hypertelorism, prognathism, and dental abnormalities; broad thumbs and great toes, variable brachydactyly-syndactyly, and having normal intelligence.
The clinical features of PS type II are cloverleaf skull (Kleeblattschadel type craniosynostosis), which is usually associated with hydrocephalus, maxillary hypoplasia with resultant proptosis, a “beak-shaped” nose, inferiorly displaced ears and ankylosis of elbow joints. It is usually associated with mental and neurological impairment and visceral abnormalities.
The clinical findings in patients with PS type III are like those present in PS type II, except for the cloverleaf skull deformity. Additional features include short anterior cranial fossa base, natal teeth, proptosis, and various visceral abnormalities (hydronephrosis, pelvic kidneys, and hypoplastic gallbladder). In PS III also, patients have mental and neurological maldevelopment and may develop seizures after birth.
Tracheal cartilaginous sleeve (TCS) is an airway malformation, seen in PS, in which distinct tracheal rings cannot be identified. Instead of the normal tracheal rings, a continuous segment of cartilage extends from sub-glottis to the carina. This abnormality is also seen in Apert and Crouzon syndromes. The presence of TCS can make the prognosis poor due to the ensuing respiratory complications.[8]
Sometimes, patients may have associated cleft palate, choanal atresia, tracheomalacia, a congenital fusion of vertebrae, Arnold-Chiari malformation, and imperforate anus.
The main ophthalmological findings seen in PS are proptosis, squint, papilledema, and iris colobomas.[9]
The diagnosis of PS is mainly clinical. A provisional diagnosis is made based on the presence of craniosynostosis and brachysyndactyly, along with the features already described. Suspected children require genetic testing and mutation analysis of FGFR1 (exon 7), FGFR2 (exons 8 and 10), and FGFR 3 (exon7).[6]
Sonographic signs of Pfeiffer syndrome include craniofacial anomalies such as brachycephaly, acrocephaly, craniosynostosis, hypertelorism, small nose, and low nasal bridge, and hand and feet anomalies such as syndactyly, broad thumb, and big toe.[10]
Experience with corrective surgery is limited. The main aims of surgery are to decompress the brain by providing adequate intracranial volume, increase the infraorbital volume to accommodate the globe and to widen the nasopharynx by the advancement of the naso-maxillary-zygomatic complex.[11]
Multiple staged surgeries are the general treatment plan for patients with PS. A suturectomy is done in the first year of life to open the intracranial space allowing brain growth.[12] Cosmetic surgical repair can be done for other abnormalities.
Patients having TCS usually requires tracheostomy, mainly to treat obstructive sleep apnea that results from maxillary hypoplasia, choanal stenosis, and macroglossia. The trachea will be rigid in these patients, and this makes appropriate sizing of tracheostomy tubes difficult. This may, in turn, lead to increased formation of granulation tissue and associated complications. The parents of any child having TCS should be counseled regarding the need for tracheostomy, which can, later on, affect the prognosis and quality of life.
The main differential diagnosis of PS is other craniosynostosis syndromes. These include:
PS is closely related to Apert syndrome, but they are genetically distinct, and Apert does not have the cloverleaf skull or proptosis seen in PS. Crouzon syndrome lacks the extremity anomalies seen in PS. Phenotypic features of PS may overlap with Muenke syndrome, which is caused by a specific FGFR3 mutation. Saethre-Chotzen syndrome and Jackson-Weiss syndrome are the other differential diagnosis of PS since broad toes may be a common feature.[6]
Antley-Bixler syndrome is a less common craniosynostosis syndrome, with some findings overlapping with PS type II. Antley-Bixler syndrome is an autosomal recessive condition associated with craniosynostosis (but not cloverleaf skull), radiohumeral synostosis (but not complete elbow ankylosis), femoral bowing, and various visceral anomalies. However, the visceral anomalies seen in the Antley-Bixler syndrome are usually genital.[7]
Type I PS has a relatively good prognosis for the intellectual outcome. The prognosis for types II and III is very poor due to neurodevelopmental complications, with death in childhood common.[7]
A patient’s prognosis depends on the severity of the syndrome, but craniofacial appearance usually improves with age. More recently, Robin et al. reviewed a clinical course of seven children with Pfeiffer syndrome type III and found that, while the children had severe manifestations, they had favorable outcomes with aggressive medical and surgical management.[13]
The main complications that can arise as a part of this syndrome are:
The only preventive measure against the occurrence of PS is genetic counseling.
Craniosynostosis, in association with facial bone maldevelopment and brachysyndactyly, are the major diagnostic clues for PS.[6]
Elbow ankylosis, cloverleaf skull, broad toes, and visceral anomalies are typical of PS, type II.
Type III PS is almost similar to type II except in the absence of a cloverleaf skull.
Visceral anomalies are common in types II and III PS.
An interprofessional approach to care, including neurosurgery, pediatrics, orthopedics, plastics, optometry, and ophthalmology, yields the most success. Special education programs and plans to identify a child’s strengths and weaknesses; and further development of a plan to improve the weaknesses identified are needed. Patients require holistic care including physiotherapy, occupational therapy, speech therapy and help and support for the visually impaired, and for school-age children, appropriately changed curricula and learning space. Development nurses are involved in ongoing care, monitoring patients, and facilitating referrals. [Level 5]
[1] | Tokumaru AM,Barkovich AJ,Ciricillo SF,Edwards MS, Skull base and calvarial deformities: association with intracranial changes in craniofacial syndromes. AJNR. American journal of neuroradiology. 1996 Apr [PubMed PMID: 8730180] |
[2] | PFEIFFER RA, [DOMINANT HEREDITARY ACROCEPHALOSYNDACTYLIA]. Zeitschrift fur Kinderheilkunde. 1964 Sep 16 [PubMed PMID: 14316612] |
[3] | Oyamada MK,Ferreira HS,Hoff M, Pfeiffer Syndrome type 2--case report. Sao Paulo medical journal = Revista paulista de medicina. 2003 Jul 1 [PubMed PMID: 14595512] |
[4] | Lajeunie E,Heuertz S,El Ghouzzi V,Martinovic J,Renier D,Le Merrer M,Bonaventure J, Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome. European journal of human genetics : EJHG. 2006 Mar [PubMed PMID: 16418739] |
[5] | Muenke M,Schell U,Hehr A,Robin NH,Losken HW,Schinzel A,Pulleyn LJ,Rutland P,Reardon W,Malcolm S, A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome. Nature genetics. 1994 Nov [PubMed PMID: 7874169] |
[6] | Vogels A,Fryns JP, Pfeiffer syndrome. Orphanet journal of rare diseases. 2006 Jun 1 [PubMed PMID: 16740155] |
[7] | Herman TE,Siegel MJ, Pfeiffer syndrome, type II. Journal of perinatology : official journal of the California Perinatal Association. 2001 Dec [PubMed PMID: 11774022] |
[8] | Hockstein NG,McDonald-McGinn D,Zackai E,Bartlett S,Huff DS,Jacobs IN, Tracheal anomalies in Pfeiffer syndrome. Archives of otolaryngology--head [PubMed PMID: 15545585] |
[9] | Clark JD,Compton CJ,Tahiri Y,Nunery WR,Harold Lee HB, Ophthalmic considerations in patients with Pfeiffer syndrome. American journal of ophthalmology case reports. 2016 Jul [PubMed PMID: 29503887] |
[10] | Medina M,Cortés E,Eguiluz I,Barber MA, Three-dimensional features of Pfeiffer syndrome. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2009 Jun [PubMed PMID: 19232609] |
[11] | Kroczek RA,Mühlbauer W,Zimmermann I, Cloverleaf skull associated with Pfeiffer syndrome: pathology and management. European journal of pediatrics. 1986 Oct [PubMed PMID: 3792393] |
[12] | Park MS,Yoo JE,Chung J,Yoon SH, A case of Pfeiffer syndrome. Journal of Korean medical science. 2006 Apr [PubMed PMID: 16614535] |
[13] | Morray JP,Geiduschek JM,Ramamoorthy C,Haberkern CM,Hackel A,Caplan RA,Domino KB,Posner K,Cheney FW, Anesthesia-related cardiac arrest in children: initial findings of the Pediatric Perioperative Cardiac Arrest (POCA) Registry. Anesthesiology. 2000 Jul [PubMed PMID: 10861140] |